Rhovac CEO quits after failed study

A little over a month ago, Rhovac’s lead candidate failed in clinical testing. The firm’s CEO has now tendered his resignation.

Photo: Frank Molter/AP/Ritzau Scanpix

Anders Månsson’s days as chief executive of biotech firm Rhovac are numbered, as he has announced his intention to leave his role no later than Sept. 30, according to a Friday press release.

“I wish Anders Månsson all the best in his new endeavors and sincerely thank him for his period as CEO of Rhovac. Anders did an excellent job, not least regarding the company’s communication, both in success and adversity. We had a well-prepared exit process that could have been executed if only the crucial study, Bravac, had reached its primary objective,” Gunnar Gårdemyr, chairman of Rhovac’s board, says in the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs